Cargando…
Determination of neutralising anti-SARS-CoV-2 antibody half-life in COVID-19 convalescent donors
Despite the burgeoning field of coronavirus disease-19 (COVID-19) research, the persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralising antibodies remains unclear. This study validated two high-throughput immunological methods for use as surrogate live virus neutrali...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8489294/ https://www.ncbi.nlm.nih.gov/pubmed/34619377 http://dx.doi.org/10.1016/j.clim.2021.108871 |
_version_ | 1784578322866372608 |
---|---|
author | Barnes, Thomas W. Schulte-Pelkum, Johannes Steller, Laura Filchtinski, Daniel Jenness, Robin Williams, Michelle R. Kober, Christina Manni, Sandro Hauser, Thomas Hahn, Aaron Kalina, Uwe Simon, Toby L. Schuetz, Patrick Roth, Nathan J. |
author_facet | Barnes, Thomas W. Schulte-Pelkum, Johannes Steller, Laura Filchtinski, Daniel Jenness, Robin Williams, Michelle R. Kober, Christina Manni, Sandro Hauser, Thomas Hahn, Aaron Kalina, Uwe Simon, Toby L. Schuetz, Patrick Roth, Nathan J. |
author_sort | Barnes, Thomas W. |
collection | PubMed |
description | Despite the burgeoning field of coronavirus disease-19 (COVID-19) research, the persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralising antibodies remains unclear. This study validated two high-throughput immunological methods for use as surrogate live virus neutralisation assays and employed them to examine the half-life of SARS-CoV-2 neutralising antibodies in convalescent plasma donations made by 42 repeat donors between April and September 2020. SARS-CoV-2 neutralising antibody titres decreased over time but typically remained above the methods' diagnostic cut-offs. Using this longitudinal data, the average half-life of SARS-CoV-2 neutralising antibodies was determined to be 20.4 days. SARS-CoV-2 neutralising antibody titres appear to persist in the majority of donors for several months. Whether these titres confer protection against re-infection requires further study and is of particular relevance as COVID-19 vaccines become widely available. |
format | Online Article Text |
id | pubmed-8489294 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Authors. Published by Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84892942021-10-04 Determination of neutralising anti-SARS-CoV-2 antibody half-life in COVID-19 convalescent donors Barnes, Thomas W. Schulte-Pelkum, Johannes Steller, Laura Filchtinski, Daniel Jenness, Robin Williams, Michelle R. Kober, Christina Manni, Sandro Hauser, Thomas Hahn, Aaron Kalina, Uwe Simon, Toby L. Schuetz, Patrick Roth, Nathan J. Clin Immunol Article Despite the burgeoning field of coronavirus disease-19 (COVID-19) research, the persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralising antibodies remains unclear. This study validated two high-throughput immunological methods for use as surrogate live virus neutralisation assays and employed them to examine the half-life of SARS-CoV-2 neutralising antibodies in convalescent plasma donations made by 42 repeat donors between April and September 2020. SARS-CoV-2 neutralising antibody titres decreased over time but typically remained above the methods' diagnostic cut-offs. Using this longitudinal data, the average half-life of SARS-CoV-2 neutralising antibodies was determined to be 20.4 days. SARS-CoV-2 neutralising antibody titres appear to persist in the majority of donors for several months. Whether these titres confer protection against re-infection requires further study and is of particular relevance as COVID-19 vaccines become widely available. The Authors. Published by Elsevier Inc. 2021-11 2021-10-04 /pmc/articles/PMC8489294/ /pubmed/34619377 http://dx.doi.org/10.1016/j.clim.2021.108871 Text en © 2021 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Barnes, Thomas W. Schulte-Pelkum, Johannes Steller, Laura Filchtinski, Daniel Jenness, Robin Williams, Michelle R. Kober, Christina Manni, Sandro Hauser, Thomas Hahn, Aaron Kalina, Uwe Simon, Toby L. Schuetz, Patrick Roth, Nathan J. Determination of neutralising anti-SARS-CoV-2 antibody half-life in COVID-19 convalescent donors |
title | Determination of neutralising anti-SARS-CoV-2 antibody half-life in COVID-19 convalescent donors |
title_full | Determination of neutralising anti-SARS-CoV-2 antibody half-life in COVID-19 convalescent donors |
title_fullStr | Determination of neutralising anti-SARS-CoV-2 antibody half-life in COVID-19 convalescent donors |
title_full_unstemmed | Determination of neutralising anti-SARS-CoV-2 antibody half-life in COVID-19 convalescent donors |
title_short | Determination of neutralising anti-SARS-CoV-2 antibody half-life in COVID-19 convalescent donors |
title_sort | determination of neutralising anti-sars-cov-2 antibody half-life in covid-19 convalescent donors |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8489294/ https://www.ncbi.nlm.nih.gov/pubmed/34619377 http://dx.doi.org/10.1016/j.clim.2021.108871 |
work_keys_str_mv | AT barnesthomasw determinationofneutralisingantisarscov2antibodyhalflifeincovid19convalescentdonors AT schultepelkumjohannes determinationofneutralisingantisarscov2antibodyhalflifeincovid19convalescentdonors AT stellerlaura determinationofneutralisingantisarscov2antibodyhalflifeincovid19convalescentdonors AT filchtinskidaniel determinationofneutralisingantisarscov2antibodyhalflifeincovid19convalescentdonors AT jennessrobin determinationofneutralisingantisarscov2antibodyhalflifeincovid19convalescentdonors AT williamsmicheller determinationofneutralisingantisarscov2antibodyhalflifeincovid19convalescentdonors AT koberchristina determinationofneutralisingantisarscov2antibodyhalflifeincovid19convalescentdonors AT mannisandro determinationofneutralisingantisarscov2antibodyhalflifeincovid19convalescentdonors AT hauserthomas determinationofneutralisingantisarscov2antibodyhalflifeincovid19convalescentdonors AT hahnaaron determinationofneutralisingantisarscov2antibodyhalflifeincovid19convalescentdonors AT kalinauwe determinationofneutralisingantisarscov2antibodyhalflifeincovid19convalescentdonors AT simontobyl determinationofneutralisingantisarscov2antibodyhalflifeincovid19convalescentdonors AT schuetzpatrick determinationofneutralisingantisarscov2antibodyhalflifeincovid19convalescentdonors AT rothnathanj determinationofneutralisingantisarscov2antibodyhalflifeincovid19convalescentdonors |